Unigestion Holding SA Sells 60,300 Shares of McKesson Co. (NYSE:MCK)

Unigestion Holding SA lessened its stake in shares of McKesson Co. (NYSE:MCK) by 73.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,750 shares of the company’s stock after selling 60,300 shares during the quarter. Unigestion Holding SA’s holdings in McKesson were worth $10,739,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. ORG Partners LLC raised its stake in shares of McKesson by 36.9% in the second quarter. ORG Partners LLC now owns 371 shares of the company’s stock valued at $218,000 after purchasing an additional 100 shares in the last quarter. DeDora Capital Inc. lifted its position in shares of McKesson by 6.5% during the 2nd quarter. DeDora Capital Inc. now owns 1,030 shares of the company’s stock worth $602,000 after buying an additional 63 shares during the period. Founders Capital Management LLC boosted its stake in McKesson by 11.8% in the 2nd quarter. Founders Capital Management LLC now owns 1,137 shares of the company’s stock valued at $664,000 after buying an additional 120 shares in the last quarter. Narus Financial Partners LLC acquired a new stake in McKesson in the 2nd quarter valued at $210,000. Finally, Miracle Mile Advisors LLC grew its position in McKesson by 55.8% in the second quarter. Miracle Mile Advisors LLC now owns 874 shares of the company’s stock valued at $510,000 after acquiring an additional 313 shares during the period. 85.07% of the stock is owned by institutional investors.

Insider Transactions at McKesson

In related news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $602.81, for a total value of $349,026.99. Following the completion of the transaction, the executive vice president now directly owns 1,443 shares of the company’s stock, valued at approximately $869,854.83. This trade represents a 28.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.11% of the company’s stock.

McKesson Trading Down 1.3 %

Shares of NYSE MCK opened at $584.07 on Wednesday. The firm has a market capitalization of $74.14 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 1.30 and a beta of 0.49. The firm’s 50-day moving average is $556.78 and its 200-day moving average is $562.15. McKesson Co. has a 1 year low of $431.35 and a 1 year high of $637.51.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, topping analysts’ consensus estimates of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The company had revenue of $93.65 billion for the quarter, compared to analyst estimates of $89.33 billion. During the same quarter last year, the firm posted $6.23 earnings per share. McKesson’s revenue was up 21.3% compared to the same quarter last year. As a group, equities research analysts anticipate that McKesson Co. will post 32.73 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Investors of record on Monday, December 2nd will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Monday, December 2nd. McKesson’s dividend payout ratio is presently 14.71%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on MCK shares. StockNews.com upgraded shares of McKesson from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Evercore ISI raised their price objective on shares of McKesson from $560.00 to $680.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Citigroup lifted their target price on shares of McKesson from $630.00 to $713.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft decreased their price target on McKesson from $623.00 to $579.00 and set a “buy” rating on the stock in a research report on Wednesday, September 25th. Finally, Wells Fargo & Company cut their price objective on McKesson from $576.00 to $535.00 and set an “equal weight” rating for the company in a research report on Friday, September 13th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and a consensus target price of $635.86.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.